|
1
|
Ferrara F and Schiffer CA: Acute myeloid
leukaemia in adults. Lancet. 381:484–495. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sabattini E, Bacci F, Sagramoso C and
Pileri SA: WHO classification of tumours of haematopoietic and
lymphoid tissues in 2008: an overview. Pathologica. 102:83–87.
2010.PubMed/NCBI
|
|
3
|
Peterson LF, Boyapati A, Ahn EY, Biggs JR,
Okumura AJ, Lo MC, et al: Acute myeloid leukemia with the 8q22;
21q22 translocation: secondary mutational events and alternative t
(8;21) transcripts. Blood. 110:799–805. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Steffen B, Knop M, Bergholz U, Vakhrusheva
O, Rode M, Köhler G, et al: AML1/ETO induces self-renewal in
hematopoietic progenitor cells via the Groucho-related
amino-terminal AES protein. Blood. 117:4328–4337. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gardini A, Cesaroni M, Luzi L, Okumura AJ,
Biggs JR, Minardi SP, et al: AML1/ETO oncoprotein is directed to
AML1 binding regions and co-localizes with AML1 and HEB on its
targets. PLoS Genet. 4:e10002752008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Quintás-Cardama A, Ravandi F, Liu-Dumlao
T, Brandt M, Faderl S, Pierce S, et al: Epigenetic therapy is
associated with similar survival compared with intensive
chemotherapy in older patients with newly diagnosed acute myeloid
leukemia. Blood. 120:4840–4845. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tallman MS: Novel therapeutic strategies
for AML in 2012. Hematology. 17(Suppl 1): 43–46. 2012.
|
|
8
|
Lengfelder E, Hanfstein B, Haferlach C,
Braess J, Krug U, Spiekermann K, et al: Outcome of elderly patients
with acute promyelocytic leukemia: results of the German Acute
Myeloid Leukemia Cooperative Group. Ann Hematol. 92:41–52. 2013.
View Article : Google Scholar :
|
|
9
|
Burnett AK, Hills RK, Milligan DW,
Goldstone AH, Prentice AG, McMullin MF, et al: Attempts to optimize
induction and consolidation treatment in acute myeloid leukemia:
results of the MRC AML12 trial. J Clin Oncol. 28:586–595. 2010.
View Article : Google Scholar
|
|
10
|
Buchner T, Berdel WE, Haferlach C,
Haferlach T, Schnittger S, Muller-Tidow C, et al: Age-related risk
profile and chemotherapy dose response in acute myeloid leukemia: a
study by the German acute myeloid leukemia cooperative group. J
Clin Oncol. 27:61–69. 2009. View Article : Google Scholar
|
|
11
|
Kasibhatla S, Jessen KA, Maliartchouk S,
Wang JY, English NM, Drewe J, et al: A role for transferrin
receptor in triggering apoptosis when targeted with gambogic acid.
Proc Natl Acad Sci USA. 102:12095–12100. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tan W, Lu J, Huang M, Li Y, Chen M, Wu G,
et al: Anti-cancer natural products isolated from chinese medicinal
herbs. Chin Med. 6:272011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Baumann S, Fas SC, Giaisi M, Muller WW,
Merling A, Gülow K, et al: Wogonin preferentially kills malignant
lymphocytes and suppresses T-cell tumor growth by inducing
PLCgamma1- and Ca2+-dependent apoptosis. Blood. 111:2354–2363.
2008. View Article : Google Scholar
|
|
14
|
Ramasamy K, Dwyer-Nield LD, Serkova NJ,
Hasebroock KM, Tyagi A, Raina K, et al: Silibinin prevents lung
tumorigenesis in wild-type but not in iNOS-/-mice: potential of
real-time micro-CT in lung cancer chemoprevention studies. Clin
Cancer Res. 17:753–761. 2011. View Article : Google Scholar :
|
|
15
|
Singh T, Vaid M, Katiyar N, Sharma S and
Katiyar SK: Berberine, an isoquinoline alkaloid, inhibits melanoma
cancer cell migration by reducing the expressions of
cyclooxygenase-2, prostaglandin E 2 and prostaglandin E 2
receptors. Carcinogenesis. 32:86–92. 2011. View Article : Google Scholar
|
|
16
|
Zhou GB, Kang H, Wang L, Gao L, Liu P, Xie
J, et al: Oridonin, a diterpenoid extracted from medicinal herbs,
targets AML1-ETO fusion protein and shows potent antitumor activity
with low adverse effects on t (8;21) leukemia in vitro and in vivo.
Blood. 109:3441–3450. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ola MS, Nawaz M and Ahsan H: Role of Bcl-2
family proteins and caspases in the regulation of apoptosis. Mol
Cell Biochem. 351:41–58. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hensley P, Mishra M and Kyprianou N:
Targeting caspases in cancer therapeutics. Biol Chem. 394:831–843.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
von Schwarzenberg K and Vollmar AM:
Targeting apoptosis pathways by natural compounds in cancer: marine
compounds as lead structures and chemical tools for cancer therapy.
Cancer Lett. 332:295–303. 2013. View Article : Google Scholar
|
|
20
|
Oltersdorf T, Elmore SW, Shoemaker AR,
Armstrong RC, Augeri DJ, Belli BA, et al: An inhibitor of Bcl-2
family proteins induces regression of solid tumours. Nature.
435:677–681. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Czabotar PE, Lessene G, Strasser A and
Adams JM: Control of apoptosis by the BCL-2 protein family:
implications for physiology and therapy. Nat Rev Mol Cell Biol.
15:49–63. 2014. View
Article : Google Scholar
|
|
22
|
Licht JD: AML1 and the AML1-ETO fusion
protein in the pathogenesis of t (8;21) AML. Oncogene.
20:5660–5679. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang L, Zhao WL, Yan JS, Liu P, Sun HP,
Zhou GB, et al: Eriocalyxin B induces apoptosis of t (8;21)
leukemia cells through NF-kappaB and MAPK signaling pathways and
triggers degradation of AML1-ETO oncoprotein in a
caspase-3-dependent manner. Cell Death Differ. 14:306–317. 2007.
View Article : Google Scholar
|
